This trial is testing whether a drug called rFVIIa can improve outcomes for people who have had a spontaneous intracerebral hemorrhage (ICH), if it is given within 120 minutes of the stroke.
1 Primary · 3 Secondary · Reporting Duration: 180 days
Active Control
Non-Treatment Group
860 Total Participants · 2 Treatment Groups
Primary Treatment: Recombinant Activated Factor VII (rFVIIa) · Has Placebo Group · Phase 3
Age 18 - 80 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: